Related Experiment Video

Updated: May 26, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

E Baudin1, S Leboulleux, A Al Ghuzlan

  • 1Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ. Paris-Sud, Villejuif, France. baudin@igr.fr

Hormones & Cancer
|December 14, 2011
PubMed

Insights

Advanced adrenocortical carcinoma (ACC) has a poor prognosis. Mitotane treatment requires careful monitoring for optimal outcomes, and new research protocols are essential for improving patient survival.

Area of Science:

  • Endocrinology
  • Oncology

Background:

  • Advanced adrenocortical carcinoma (ACC) presents a dismal yet heterogeneous prognosis.
  • Mitotane, approved in 2011, is the sole drug for advanced ACC in Europe and the US.
  • Mitotane's antisecretory and antiproliferative effects are delayed, necessitating diligent monitoring.

Purpose of the Study:

  • To review the current treatment landscape for advanced adrenocortical carcinoma.
  • To highlight the importance of monitoring mitotane plasma levels and treatment response.
  • To emphasize the need for novel therapeutic strategies and research protocols.

Main Methods:

  • Literature review of existing treatment guidelines and clinical data for advanced ACC.
  • Analysis of mitotane's pharmacological profile, including its effects and monitoring requirements.
  • Discussion of the role of locoregional therapies and the potential for improved survival.

Main Results:

  • Mitotane treatment requires careful biological and morphological evaluation alongside plasma level monitoring.
  • Combined polychemotherapy has not demonstrated superior activity, favoring less toxic regimens.
  • Objective tumor response and high mitotane plasma levels correlate with prolonged survival.

Conclusions:

  • The least toxic regimen should be prioritized in routine care for advanced ACC.
  • Locoregional therapies, including surgery, are vital components of the therapeutic strategy.
  • International collaboration and comprehensive data collection are crucial for advancing ACC research and treatment.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...